Pop Quiz

FIGARO-DKD Trial Outcomes

AUTHOR:
James Matera, DO
Practicing Nephrologist, Senior Vice President for Medical Affairs, and Chief Medical Officer
CentraState Medical Center, Freehold, New Jersey

A recent article highlighted results of the FIGARO-DKD trial, where wider ranges of chronic kidney disease (CKD, stage 2 to 4) were reviewed. This trial also showed that finerenone reduced cardiovascular adverse events in patients with more advanced CKD.¹

Reference:

Pitt B, Filippatos G, Agarwal R, et al; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. New Engl J Med. Published online August 28, 2021. https://doi.org/10.1056/nejmoa2110956

Current Consultant Issue

Previous Issues

Early View

Research Summaries

Conference Coverage

Fatigue, Headache Are Primary Symptoms of Long COVID Among Patients 21 Years of Age or Younger

10/07/2024

Anthony Calabro, MA

Researchers aimed to describe the most common symptoms of long COVID and the progression of symptoms over time. They presented their findings at IDWeek 2023 in Boston, Massachusetts.

10/07/2024

Depression Care360

Depression Rates Saw Hike in Last 4 Years, During Pandemic Especially

10/02/2024

Rates of clinically diagnosed depression and anxiety without depression increased between 2017 and 2021, especially during the COVID-19 pandemic, according to recent cohort study results published in JAMA...

10/02/2024

Research Summary

Research Summary

Can Mindfulness-Based Stress Reduction Improve Quality of Life for Patients With HIV?

09/30/2024

Miranda Manier, BA

Researchers conducted a randomized trial to evaluate the impact of mindfulness-based stress reduction on depression and quality of life in older adults living with HIV and cognitive impairment.

09/30/2024

Conference Coverage

Long-Term Follow-Up Shows Continued Efficacy of Iomab B-Led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML

09/30/2024

Anthony Calabro, MA

In a long-term follow-up to SIERRA, a multicenter, randomized, controlled phase 3 study, researchers found that patients 55 years of age or older with active relapsed or refractory acute myeloid leukemia...

09/30/2024

Research Summary

Pembrolizumab Plus Chemotherapy Did Not Improve Disease-Free Survival in Patients With High-Risk Endometrial Cancer

09/30/2024

Anthony Calabro, MA

Although the immunotherapy plus chemotherapy did not improve disease-free survival (DFS) in newly diagnosed, high-risk patients with endometrial cancer, the combination therapy did improve DFS for patients...

09/30/2024

Trending Articles

Pop Quiz

Treatment Strategies For Patients With PsA Who Do Not Respond To TNFi

09/10/2024

In an interview with Consultant360, study author Ying-Ying Leung, MD, MBChB said this about the treatment strategies for patients with PsA who do not respond to tumor necrosis factor inhibitors:...

09/10/2024

Pop Quiz

Onset of Rheumatoid Arthritis

09/08/2024

Rheumatoid arthritis (RA) can begin at any age, but the likelihood increases with age. What is the approximate age when the onset of RA is most likely?

09/08/2024